HomeCompareCNBI vs PLD

CNBI vs PLD: Dividend Comparison 2026

CNBI yields 1000000.00% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNBI wins by $4.7683925249533696e+36M in total portfolio value
10 years
CNBI
CNBI
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full CNBI calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — CNBI vs PLD

📍 CNBI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNBIPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNBI + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNBI pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNBI
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, CNBI beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNBI + PLD for your $10,000?

CNBI: 50%PLD: 50%
100% PLD50/50100% CNBI
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CNBI
No analyst data
Altman Z
2.3
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNBI buys
0
PLD buys
0
No recent congressional trades found for CNBI or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNBIPLD
Forward yield1000000.00%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$4.7683925249533696e+36M$5.91M
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$4,750,725.19
Total dividends collected$4.7683311610149396e+36M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CNBI vs PLD ($10,000, DRIP)

YearCNBI PortfolioCNBI Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,241$540.96+$100.00MCNBI
2$934,786,450,701$934,679,439,252.34$13,019$991.13+$934786.44MCNBI
3$8,165,787,108,578,292$8,164,786,887,076,042.00$15,801$1,870.97+$8165787108.56MCNBI
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$20,609$3,701.21+$66665884190957.63MCNBI
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$29,919$7,867.97+$508662171058048128.00MCNBI
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$50,631$18,617.74+$3.62723524842849e+21MCNBI
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$105,528$51,352.20+$2.417368115915061e+25MCNBI
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$287,364$174,449.42+$1.5056740286145463e+29MCNBI
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$1,081,760$774,280.77+$8.764771002818475e+32MCNBI
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$5,908,209$4,750,725.19+$4.7683925249533696e+36MCNBI

CNBI vs PLD: Complete Analysis 2026

CNBIStock

China BCT Pharmacy Group, Inc., through its subsidiaries, operates as an integrated pharmaceutical company in the People's Republic of China. It operates through three segments: Pharmaceutical Distribution, Retail Pharmacy, and Manufacturing Pharmacy. The Pharmaceutical Distribution segment purchases pharmaceutical products from suppliers and distributes them to hospitals, retail drug stores, other pharmaceutical wholesalers, clinics, medical centers, and individuals. It offers approximately 8,000 pharmaceutical and healthcare products, including branded and generic prescription medicines, over-the counter medicines, and Western and Chinese medicines, as well as personal care products and medical supplies, Chinese herbs, and medical instruments. The Retail Pharmacy segment operates a retail pharmacy network of 196 directly owned stores, primarily in Guangxi province under the Baicaotang name. The retail stores provide professional pharmaceutical services, and supply various medicines, such as prescription medicines, over-the-counter medicines, Chinese herbal medicine, roughly processed Chinese herbal medicine, family planning products, and other pharmaceutical and healthcare products. The Manufacturing Pharmacy segment manufactures and sells generic and clinic drugs, such as traditional anti-inflammatory and antibacterial drugs, cancer treatment drugs, cardio-vascular disease drugs, and hepatitis drugs under the Asio name. Its products comprise Levodopa, Tabellae Sarcandrae, Rotandine Sulfate, Corydalis Saxicola Bunting, and Ethacridine Lactate injection. The company was formerly known as China Baicaotang Medicine Limited and changed its name to China BCT Pharmacy Group, Inc. in March 2010. China BCT Pharmacy Group, Inc. is headquartered in Liuzhou, the People's Republic of China.

Full CNBI Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CNBI vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNBI vs SCHDCNBI vs JEPICNBI vs OCNBI vs KOCNBI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.